Forum

Post edited 8:42 pm – July 20, 2010 by FM2020

Three papers have shown that resveratrol does not directly activate SIRT1. Maybe that does not matter, and that there is an indirect route, or maybe all three studies are flawed.

This is what Dr. Sinclair told the New York Times last August:

  "the results from the Sirtris compounds are promising and will be submitted for publication in coming months."

It has been almost a year, and from what I can tell, almost nothing has been published. Dr. Westphal said a few weeks ago a paper was being submitted, so maybe that is under review.

The SRT 501 multipe meyeloma trial was suspened this spring because some patients developed kidney problems. It isn't clear that SRT 501 was the reason, and maybe it is good news that some patients wanted to keep taking it. Note also that SRT 501 results for the liver/colon cancer trial were never published after the study ended last December.

So there isn't much good news coming out of GSK/Sirtis recently, but maybe that will change soon. Interesting that the book was delated a year,  though.

Dr. Sinclair was writing a book called Just in Time, scheduled for July 2010. Here is a quote from Forbes:

 "We have split the atom in this field," he (Sinclair) proclaims. "It could be one pill for 20 diseases at once." He figures the compounds will save trillions in medical costs as people live to a ripe old age with few health problems. He is writing a book on his vision: Just in Time.

[further down the article] But just when you think he (Sinclair) is about to go too far, he backs off, admitting that it is possible that the sirtuin research won't pan out in humans. "I don't know if it is me who is going to be successful," he says. A moment later he is insisting that if not he, then someone will eventually develop drugs against aging.

If this site is correct, the book has been delayed a year:

Publisher: Free Press (Oct 2011)

http://www.flipkart.com/just-t…..1439135762